These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3126247)

  • 41. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
    Kanellakopoulou K; Sarafis P; Galani I; Giamarellou H; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):33-9. PubMed ID: 18538547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Host range variability in the transfer of antibiotic resistance determinants from Pseudomonas aeruginosa strains.
    Blahová J; Králiková K; Krcméry V; Schäfer V
    J Chemother; 2000 Jun; 12(3):199-203. PubMed ID: 10877513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Activities of antipseudomonal agents against clinical isolates of Pseudomonas aeruginosa].
    Murase M; Miyamoto H; Handa T; Saheki S; Takeuchi N
    Jpn J Antibiot; 1995 Oct; 48(10):1581-9. PubMed ID: 8544340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.
    Kim CH; Kang HY; Kim BR; Jeon H; Lee YC; Lee SH; Lee JC
    J Microbiol; 2016 Jan; 54(1):44-49. PubMed ID: 26727901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chlorhexidine hypersensitivity of ciprofloxacin-resistant variants of Pseudomonas aeruginosa PAO.
    Baillie LW; Power EG; Phillips I
    J Antimicrob Chemother; 1993 Feb; 31(2):219-25. PubMed ID: 8385092
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outer membrane proteins profiles of Pseudomonas aeruginosa after the post-antibiotic effect of imipenem.
    Hostacká A; Karelová E
    Microbios; 1997; 90(362):45-50. PubMed ID: 9301070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
    Lister PD; Wolter DJ
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France.
    Diene SM; L'homme T; Bellulo S; Stremler N; Dubus JC; Mely L; Leroy S; Degand N; Rolain JM
    Int J Antimicrob Agents; 2013 Sep; 42(3):268-71. PubMed ID: 23880169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Development of resistance in imipenem therapy in Pseudomonas aeruginosa].
    Krech T; Naumann P
    Immun Infekt; 1986 Nov; 14(6):224-6. PubMed ID: 3100426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Further studies of transferable antibiotic resistance in strains of Pseudomonas aeruginosa from four clinical settings in three countries.
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K; Torsová V; Bartoníková N; Schäfer V
    J Chemother; 1998 Jun; 10(3):215-20. PubMed ID: 9669646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post-antibiotic effect of quinolones on Pseudomonas aeruginosa.
    Sood P; Mandal A; Mishra B
    J Antimicrob Chemother; 1999 Mar; 43(3):425-7. PubMed ID: 10223604
    [No Abstract]   [Full Text] [Related]  

  • 55. Efflux pump genes and antimicrobial resistance of Pseudomonas aeruginosa strains isolated from lower respiratory tract infections acquired in an intensive care unit.
    Ozer B; Duran N; Onlen Y; Savas L
    J Antibiot (Tokyo); 2012 Jan; 65(1):9-13. PubMed ID: 22086166
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resistance of Pseudomonas aeruginosa to imipenem is independent of beta-lactamase production.
    Büscher KH; Cullmann W; Opferkuch W
    J Antimicrob Chemother; 1987 May; 19(5):700-1. PubMed ID: 3112097
    [No Abstract]   [Full Text] [Related]  

  • 57. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
    Sousa D; Castelo-Corral L; Gutiérrez-Urbón JM; Molina F; López-Calviño B; Bou G; Llinares P
    J Antimicrob Chemother; 2013 Aug; 68(8):1917-25. PubMed ID: 23557925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cloning and characterization of a DNA fragment that complements the nfxB mutation in Pseudomonas aeruginosa PAO.
    Okazaki T; Iyobe S; Hashimoto H; Hirai K
    FEMS Microbiol Lett; 1991 Mar; 63(1):31-5. PubMed ID: 1904383
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents.
    Cook PP; Das TD; Gooch M; Catrou PG
    Infect Control Hosp Epidemiol; 2008 Aug; 29(8):716-22. PubMed ID: 18590455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.